Olema Oncology, Bayer Partner on Prostate Cancer Drug Trial

Olema Oncology has announced a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136. The trial will assess OP-3136 in combination with Bayer's NUBEQA® for metastatic castration-resistant prostate cancer.